Sinovac Biotech Ltd
NASDAQ:SVA
Intrinsic Value
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. [ Read More ]
The intrinsic value of one
SVA
stock under the Base Case scenario is
314.69
USD.
Compared to the current market price of 6.47 USD,
Sinovac Biotech Ltd
is
Undervalued by 98%.
Sinovac Biotech Ltd's market capitalization is 643.8m USD.
SVA stock price is 6.47 USD.
SVA stock price (6.47 USD) is 98% less than its Intrinsic Value (314.69 USD).
SVA. Open Relative Valuation
SVA.
SVA has negative Net Income for the last twelve months.
SVA's ROE (Return on Equity) for the past 12 months is negative and is equal to -4%.
SVA's Revenue has dropped by 96% over the past 12 months.
SVA's ROE (Return on Equity) has significantly decreased in the last 3 years from 20% to -4%.
SVA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 52% to -48%.
SVA's Revenue has been growing by an exceptional 25% per year for the last 3 years.
SVA has negative Operating Income for the last twelve months.
SVA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -48%.
SVA has negative Free Cash Flow for the last twelve months.
SVA's long-term assets (14B USD) exceed its long-term liabilties (5B USD).
SVA has negative Gross Profit for the last twelve months.
SVA's D/E (Debt to Equity) is very low and is equal to 0.
SVA has very high three-year average ROE (Return on Equity): 51%. The company is very efficient at transforming stockholders' equity into net income.
SVA has very high three-year average ROIC (Return on Invested Capital): 186%. The company is very efficient at using invested capital to generate operating income.
SVA's short-term assets (12B USD) exceed its short-term liabilties (1B USD).
SVA has negative Net Debt. This means that the company has more cash and short-term investments (11B USD) than debt (11m USD).
SVA's Altman Z-Score is very low and is equal to 0.6.
SVA doesn't generate enough operating income (-2B USD) to safely cover interest payments on its debt (1m USD).
Fundamental Analysis
Sinovac Biotech Ltd
Balance Sheet Decomposition
Sinovac Biotech Ltd
| Current Assets | 11.8B |
| Cash & Short-Term Investments | 11.1B |
| Receivables | 500.4m |
| Other Current Assets | 199.8m |
| Non-Current Assets | 2B |
| Long-Term Investments | 657.8m |
| PP&E | 1.1B |
| Intangibles | 8.8m |
| Other Non-Current Assets | 182.8m |
| Current Liabilities | 1.2B |
| Accounts Payable | 819.5m |
| Accrued Liabilities | 6m |
| Other Current Liabilities | 364.1m |
| Non-Current Liabilities | 3.9B |
| Long-Term Debt | 11m |
| Other Non-Current Liabilities | 3.9B |
Earnings Waterfall
Sinovac Biotech Ltd
|
Revenue
|
420.9m
USD
|
|
Cost of Revenue
|
-618.5m
USD
|
|
Gross Profit
|
-197.6m
USD
|
|
Operating Expenses
|
-1.3B
USD
|
|
Operating Income
|
-1.5B
USD
|
|
Other Expenses
|
1.1B
USD
|
|
Net Income
|
-359.7m
USD
|
Free Cash Flow Analysis
Sinovac Biotech Ltd
What is Free Cash Flow?
SVA Profitability Score
Profitability Due Diligence
Sinovac Biotech Ltd's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Sinovac Biotech Ltd's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
SVA Solvency Score
Solvency Due Diligence
Sinovac Biotech Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Sinovac Biotech Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SVA Price Targets Summary
Sinovac Biotech Ltd
Ownership
SVA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SVA Price
Sinovac Biotech Ltd
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown |
N/A
|
| Market Capitalization | 643.8m USD |
| Shares Outstanding | 99 294 704 |
| Percentage of Shares Shorted | 0.26% |
Company Profile
Sinovac Biotech Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is headquartered in Beijing, Beijing and currently employs 1,959 full-time employees. The company went IPO on 2009-11-13. The firm is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The firm's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The firm is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The firm develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
You don't have any saved screeners yet
